89bio: Despite Peer Trial Setback, Potential Remains In NASH (NASDAQ:ETNB)


Medical Development Laboratory: Caucasian Female Scientist Looking Under Microscope, Analyzes Petri Dish Sample. Specialists Working on Medicine, Biotechnology Research in Advanced Pharma Lab

ARMMY PICCA/iStock via Getty Images

89bio, Inc. (NASDAQ:ETNB) has made great progress in advancing its pipeline, especially since it has reached an agreement with regulators to advance two clinical studies using its drug pegozafermin to treat patients with NASH



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *